Multicenter, randomized phase III study of adjuvant chemotherapy for high-risk, node-negative breast cancer comparing tac with fac: 5-year efficacy analysis of the GEICAM 9805 trial

Martín, M. González; Iluch, A.; Segui, M.; Ruiz, A.; Ramos, Maritza; Cebrián, E. Adrover; Rodriguez-Lescure, A.; Große, R; Calvo, Lourdes; Antón, A.

doi:10.1200/jco.2008.26.15_suppl.542

Cited by 11 publications

(10 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There were 9 studies identifi ed from communications at the ASCO, SABCS and ESMO meetings. Finally, 24 studies were included, 17 selected for the meta-analysis (10 with docetaxel and 7 with paclitaxel) [13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29] (Table 1). The other 7 not included in the metaanalysis are second-generation trials.…”

Section: Resultsmentioning

confidence: 99%

“…Moreover, the Rosenthal index or the Q analysis for the heterogeneity can be infl uenced by the number of trials and, in this case, the number of trials of paclitaxel was lower than with docetaxel (6 vs. 10). Finally, of the 17 trials included in the meta-analysis, 4 are yet to be published [15,16,24,28].…”

Section: Limitations Of the Meta-analysis And Indirect Comparisonsmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy of taxanes as adjuvant treatment of breast cancer: a review and meta-analysis of randomised clinical trials

et al. 2011

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Limitations Of the Meta-analysis And Indirect Comparisonsmentioning

confidence: 99%

Efficacy of taxanes as adjuvant treatment of breast cancer: a review and meta-analysis of randomised clinical trials

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Die Ergebnisse zeigten nach 5 Jahren einen signifikanten Vorteil hinsichtlich des krankheitsfreien Überlebens zugunsten der kombinierten anthracyclin-und taxanhaltigen Chemotherapie TAC. Es konnte jedoch kein Unterschied für das Gesamtüberleben gezeigt werden [64].…”

Section: Zytostatische Therapieunclassified

Systemtherapie des Mammakarzinoms

Aigner

Schneeweiß

2009

Onkopipeline

View full text Add to dashboard Cite

ZUSAMMENFASSUNGDas Mammakarzinom ist weltweit der häufigste bösartige Tumor der Frau mit über 1 Mio. Neuerkrankungen pro Jahr. Die relative 5-Jahres-Überle-benszeit beträgt über alle Tumorstadien gesehen 79% und hat sich gerade innerhalb der letzten Jahre aufgrund einer effektiveren, frühzeitigeren Diagnostik und einer leitlinienorientierten Systemtherapie verbessert. Über die Bestimmung von prognostischen und prädiktiven Faktoren wird versucht, den individuellen Krankheitsverlauf möglichst genau vorherzusagen und eine Aussage über das Ansprechen auf eine spezifische Therapie zu treffen. Darauf basierend wird die leitlinienorientierte Systemtherapie zusammengestellt.Gerade die Hormon-und Chemotherapien haben sich über die letzten 25 Jahre zu einem integralen und unverzichtbaren Bestandteil sowohl in der (neo)adjuvanten als auch in der palliativen Systemtherapie entwickelt. Die Metaanalysen der Early Breast Cancer Trialists' Collaborative Group (EBCTCG) haben wiederholt gezeigt, dass die systemischen Therapien, bestehend aus zytotoxischen Chemotherapien und/oder endokrinen Therapien, sowohl das rezidivfreie Überleben als auch das Gesamtüberleben signifikant verbessern. Zusätzlich wurden in den letzten Jahren die therapeutischen Optionen der (neo)adjuvanten und palliativen Systemtherapie durch die heterogene Gruppe der neuen zielgerichteten Therapien und durch die Bisphosphonate erweitert. Aufgabe der kommenden Jahre ist es einerseits, diese Optionen rasch weiterzuentwickeln und in den Standard zu integrieren, andererseits durch eine verbesserte Prädiktion und Prognoseabschätzung die Über-, Unter-und Fehlbehandlung zu reduzieren. Schlüsselwörter: Mammakarzinom · (Neo)adjuvante/palliative Systemtherapie · Endokrine Therapie · Zytostatische Therapie · Zielgerichtete Therapie · Bisphosphonate onkopipeline 2009;2:171-84. ABSTRACT Systemic Therapy of Breast CancerBreast cancer is the most common malignancy among women worldwide, with over 1 million new cases every year. The overall 5-year survival rate for all cancer stages is 79% and could be significantly improved over the last years due to more effective and earlier diagnostics and a guideline-based systemic therapy. In order to optimize treatment, it is essential to accurately determine the patient's underlying course of disease and choose a therapy to which the individual is most likely to respond. Attention has therefore focused on the identification of novel prognostic and predictive factors.In the past 25 years, endocrine and cytotoxic therapies have developed to be an integral and essential part of the (neo)adjuvant and palliative systemic

show abstract

“…The investigators demonstrated that patients with node-negative disease did benefit significantly from the addition of a taxane to an anthracycline-based combination chemotherapy (Fig. 2) [3].…”

Section: Chemotherapy In Node-negative Diseasementioning

confidence: 99%

A New Look at Node-Negative Breast Cancer

Harbeck

Thomssen

2010

The Oncologist

View full text Add to dashboard Cite

Node-negative breast cancer is a prevalent form of the disease worldwide, particularly in regions with rigorous screening and disease awareness efforts. Although there is a common biology between node-negative and nodepositive breast tumors, it is still important to specifically address risk assessment and predictive factors in nodenegative breast cancer. The relative risks and benefits are more pronounced in these patients, but there is no single prognostic factor available for deciding whether to administer chemotherapy and selecting the best adjuvant chemotherapy regimen. In the absence of universal predictive factors, the trend is to give chemotherapy to all patients to ensure the highest possibility for cure. Tumor grade is important in that it is predictive of risk over time, but lacks standardization. Adjuvant! Online, a web-based algorithm, is also used to guide treatment decisions. Recently, the urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) biomarkers have been used to determine disease risk and, consequently, determine whether or not chemotherapy is needed. However, the assay requires a fresh-frozen tissue sample, which is not always feasible. The oncotype DX genomic assay has also been used to help prognosis estimation and treatment decisions. It is currently under evaluation in conjunction with the uPA/PAI-1 assay in the Plan B trial. The question that remains in adjuvant chemotherapy today for patients with node-negative disease is proper patient selection. Node-negative breast cancer does not automatically suggest a good prognosis, or the preclusion of chemotherapy benefits, and additional biomarkers are needed to help identify patients who do benefit from chemotherapy. The Oncologist 2010;15(suppl 5):29 -38

show abstract

Multicenter, randomized phase III study of adjuvant chemotherapy for high-risk, node-negative breast cancer comparing tac with fac: 5-year efficacy analysis of the GEICAM 9805 trial

Cited by 11 publications

References 0 publications

Efficacy of taxanes as adjuvant treatment of breast cancer: a review and meta-analysis of randomised clinical trials

Efficacy of taxanes as adjuvant treatment of breast cancer: a review and meta-analysis of randomised clinical trials

Systemtherapie des Mammakarzinoms

A New Look at Node-Negative Breast Cancer

Contact Info

Product

Resources

About